MAMuhammad Maaz Amjad

Muhammad Maaz Amjad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Muhammad Maaz Amjad has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy and Safety of Dual GLP ‐1/Glucagon Receptor Agonism in Overweight and Obesity: A Class‐Specific Systematic Review and Meta‐Analysis

    by Muhammad Maaz Amjad, Muhammad Mustafa Khan, Fatima Sarwar, Aqsa Ali, Maham Ali, Faiza Bakhash, Humna Abid, Farah Ibrahim, Kashaf Mustafa, Dur‐E‐Najaf Ali, et al.

    Background: Dual glucagon‐like peptide‐1/glucagon receptor (GLP‐1/GCGR) agonists represent a novel obesity treatment class, but existing meta‐analyses often conflate them with GIP‐containing agents (tirzepatide, retatrutide) or restrict analysis to one or two drugs, leaving class‐specific efficacy and safety incompletely characterized. Methods: We systematically searched PubMed, Embase, Cochrane Library, Scopus and ClinicalTrials.gov through 20 July 2026 for randomized controlled trials of mazdutide, survodutide, cotadutide, and efinopegdutide in adults with overweight/obesity (PROSPERO CRD420261456447). Random‐effects meta‐analysis pooled mean differences (MDs) and risk ratios (RRs) with 95% CIs; heterogeneity, subgroup, sensitivity, GRADE and publication bias analyses were performed. Results: Nineteen RCTs were included. Dual agonists significantly reduced absolute body weight (MD: −6.65 kg, moderate certainty), relative weight (MD: −7.15%), and increased likelihood of ≥ 5% weight loss (RR: 4.75, low certainty), with mazdutide and survodutide showing the largest effects. Significant improvements occurred in HbA1c, BMI, waist circumference, systolic blood pressure and triglycerides. Any adverse events were more frequent with dual agonists (RR: 1.16), while serious adverse events did not differ from controls (RR: 0.90, high certainty). Conclusion: Dual GLP‐1/GCGR agonists produce meaningful weight loss and metabolic improvements with acceptable short‐term safety, though longer head‐to‐head trials are needed to confirm durability and cardiovascular safety.

  • Influence of Lactobacillus plantarum on anthropometric and inflammatory parameters in obesity: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials

    by Muhammad Huzaifa Khattak, Syed Aqeel Abbas, Umer Zaryab, Humaira Bibi, Shahreena Athar Siddiqui, Bilal Wazir Khan, Nafila Zeeshan, Muhammad Faaz Khan, Muhammad Maaz Amjad, Naveed Ahmad Khan, et al.

    Background The global obesity epidemic, rooted in chronic inflammation and metabolic dysfunction, necessitates novel interventions; however, evidence regarding the efficacy of Lactobacillus plantarum remains inconsistent. Objective To evaluate the impact of L. plantarum on obesity-related outcomes in adults via a systematic review and meta-analysis of RCTs. Methods Following PRISMA guidelines and registered in PROSPERO (CRD420251102722), we systematically searched PubMed, Cochrane Library, and Google Scholar through May 2025. Eighteen RCTs (1310 participants) involving non-diabetic adults with BMI ≥ 25 kg/m² were included. Primary outcomes were body weight and BMI; secondary outcomes included lipid profile, glycemic indices, inflammatory biomarkers, liver enzymes, and body composition. ROB 2.0 and GRADE were used to assess bias and evidence certainty. Results L. plantarum supplementation significantly reduced body weight (MD = −1.23 kg; 95% CI: −1.97 to −0.49; p = 0.001; I² = 49%) and BMI (MD = −0.28; 95% CI: −0.54 to −0.02; p = 0.03; I² = 77%). Subgroup analysis suggested these reductions were more pronounced with multi-strain formulations than single-strain L. plantarum; however, tests for subgroup interaction were non-significant, indicating insufficient evidence to confirm a true difference in effect by formulation type. Improvements were also noted in waist circumference (MD = −1.36 cm; p = 0.003) and liver enzymes. High-certainty evidence supported body weight reduction; moderate-certainty evidence supported reductions in BMI, waist circumference, fat mass, and liver enzymes; low-certainty evidence was found for lipid, glycemic, and inflammatory outcomes. Conclusions L. plantarum, particularly in multi-strain formulations, may provide modest yet clinically meaningful benefits in obesity management. Standardized, long-term trials are warranted. Registry and registry number for systematic reviews or meta-analyses The systematic review and meta-analysis were registered on PROSPERO under the ID: CRD420251102722.

  • Clinical Outcomes of Sacituzumab Govitecan in Breast Cancer

    by Muhammad M. Amjad, Maryam Rafique, Syeda F. Hussain, Mehroz Mustafa, Tayyaba I. Qazi, Saaim Sikandar, Amir H. Khan, Hassam S. Khan, Qalb e Zainab, Ayesha Zaheer, et al.

    Objectives: Sacituzumab govitecan (SG), a Trop-2–directed antibody-drug conjugate delivering SN-38, has shown promising activity in advanced breast cancer. However, variability across trials and inclusion of nonrandomized data in prior meta-analyses limit the certainty of its efficacy and safety. This study aimed to evaluate the effectiveness and safety of SG using only randomized controlled trials (RCTs). Methods: A systematic review and meta-analysis were conducted following PRISMA guidelines. PubMed/MEDLINE, Embase, Scopus, and Cochrane Library were searched from June 2025 to April 2026. RCTs comparing SG with standard therapies in breast cancer patients were included. Outcomes included objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and grade ≥3 adverse events. Random-effects models were used to calculate pooled risk ratios (RR) and hazard ratios (HR) with 95% CIs. Risk of bias (RoB 2) and GRADE approaches were applied. Results: Six RCTs (n=2508) were included. SG significantly improved ORR (RR=1.62; 95% CI: 1.11-2.37), OS (HR=0.68; 95% CI: 0.54-0.86), and PFS (HR=0.60; 95% CI: 0.51-0.72), although heterogeneity was moderate to high in some analyses. SG was associated with a higher risk of grade ≥3 adverse events (RR=1.12; 95% CI: 1.05-1.20), particularly diarrhea and neutropenia. Subgroup and sensitivity analyses confirmed the robustness of efficacy outcomes. Conclusions: SG provides significant improvements in survival and response outcomes in advanced breast cancer, with a manageable toxicity profile. These findings support its role as an effective treatment option, particularly in pretreated patients, while highlighting the need for further research to optimize its clinical use.

  • Efficacy and safety of carboplatin-containing chemotherapy in triple-negative breast cancer: A comprehensive systematic review, meta-analysis, and trial sequential analysis with BRCA/HRD subgroup assessment

    by Muhammad Maaz Amjad, Muaz Shehzar Bashir, Khwaja Waleed Maqbool, Tayyaba Ikram Qazi, Minahil Ali, Muhammad Ahmad Idrees, Ahmad Ali, Sania Wazir, Hassam Safdar Khan, Sami Ullah, et al.

    Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options. Platinum agents, particularly carboplatin's DNA damaging properties suggest efficacy, its impact on survival outcomes and toxicity remains uncertain. Methods: PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov were searched from inception to February 2026. Phase II/III RCTs comparing carboplatin plus standard chemotherapy with standard therapy alone in TNBC were included. Primary outcomes were disease-free survival (DFS), overall survival (OS), and pathological complete response (pCR). Pooled hazard ratios (HRs) and risk ratios (RRs) were calculated using random-effects models. Results: Twenty-three trials (n = 8797) were included. Carboplatin significantly improved DFS (HR 0.68, 95% CI 0.60–0.76), OS (HR 0.65, 95% CI 0.53–0.80), and pCR (RR 1.46, 95% CI 1.30–1.64). Improvements were also observed in distant disease-free survival and recurrence-free survival. However, carboplatin was associated with increased hematological toxicities, including anemia, neutropenia, and thrombocytopenia, and higher rates of dose reduction and treatment discontinuation, though treatment-related mortality was not significant. Conclusion: Carboplatin-containing chemotherapy improves survival outcomes and pCR in TNBC. Despite increased toxicity, adverse effects are generally manageable. These findings support the incorporation of carboplatin into TNBC treatment, with careful patient selection to balance efficacy and safety.

  • Efficacy of transcranial direct current stimulation in children and adolescents with autism spectrum disorder: A systematic review and meta-analysis

    by Muhammad Maaz Amjad, Hadiya Javed, Muhammad Zuhaz Azeem, Tuyyab Anwer, Bilal Wazir Khan, Muhammad Huzaifa Khattak, Umer Zaryab Khan, Muhammad Ahmed Zahoor, Zobia Tabassum, Muhammad Ehsan, et al.